WCLC 2023 | RTOG 0617: radiation with concurrent chemotherapy and cetuximab in NSCLC

Stephen Chun, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the NRG Oncology-RTOG 0617 trial (NCT00533949), a study which compared standard-dose versus high-dose radiation with concurrent chemotherapy and determined the efficacy of cetuxumab for stage III non-small cell lung cancer (NSCLC). This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.